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Abstract
Background—The prevalence of chronic kidney disease as measured by biomarkers is 
increasing, but the recognition for this condition remains low in the USA. Little is known about 
the awareness of kidney disease at the state level.
Methods—Data from 490,302 adults aged 18 years or older in all 50 states as well as the District 
of Columbia who participated in the 2011 Behavioral Risk Factor Surveillance System were 
analyzed. Kidney disease diagnosis, a measure of individual awareness, was ascertained by 
participants’ self-report in the telephone survey. Prevalence ratios of self-reported kidney disease 
in sub-populations were estimated and tested using log-linear regression analyses with a robust 
variance estimator.
Results—The unadjusted prevalence of self-reported kidney disease was estimated to be 2.5%. 
After adjustment for age and all other selected covariates, Hispanics had a higher prevalence than 
non-Hispanic whites (adjusted prevalence ratio 1.2, 95% CI 1.0–1.4). Persons who were 
unemployed (adjusted prevalence ratio 1.4, 95% CI 1.2–1.5) had a higher prevalence than those 
who were employed. Persons who had hypertension (adjusted prevalence ratio 1.9, 95% CI 1.7–
2.1), diabetes (adjusted prevalence ratio 1.7, 95% CI 1.5–1.8), cardiovascular disease (coronary 
heart disease, myocardial infarction or stroke; adjusted prevalence ratio 1.5, 95% CI 1.4–1.6) or 
cancer (adjusted prevalence ratio 1.5, 95% CI 1.3–1.6) had a higher prevalence of self-reported 
kidney disease than those without these conditions.
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Conclusion—The overall awareness of kidney disease was low in the general population. Efforts 
are needed to promote the awareness and early detection of kidney disease in public health 
services and clinical practice.
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Introduction
Chronic kidney disease (CKD), defined as the presence of kidney damage (i.e. albuminuria) 
or decreased kidney function (i.e. glomerular filtration rate <60 ml/min/1.73 m2) irrespective 
of cause for 3 months or more, has emerged as a public health concern [1, 2]. Persons with 
CKD are at increased risk of developing kidney failure, complications from reduced kidney 
function and cardiovascular diseases [1, 2]. Moreover, persons with CKD are more likely to 
die from all causes, particularly from cardiovascular diseases [1–3].
In the US adult population, the prevalence of CKD based on biochemical markers was 
estimated to be 10% during 1988–1994, 13% during 1999–2004 and 14% during 2005–2010 
in adults aged 20 years or older based on data from the National Health and Nutrition 
Examination Survey (NHANES) [4, 5]. The prevalence of CKD was estimated to be 26% 
among high-risk persons with diabetes or hypertension or with a first-order relative with 
diabetes, hypertension or kidney disease during 2000–2009 based on data from the National 
Kidney Foundation’s Kidney Early Evaluation Program (KEEP) [6]. Nevertheless, 
awareness of kidney disease remains low such that only 6% of adults with CKD stage 1–4 
reported being told that they had weak or failing kidneys [7]. About 9% of the participants in 
the KEEP study reported being aware of kidney disease [6]. The differences in the 
prevalence and awareness estimates of CKD between NHANES data and KEEP data could 
be due to the study populations represented (general population vs. high-risk population). 
However, little is known about the awareness of kidney disease among US adults at the state 
level and among sub-populations in the general population.
The prevalence of kidney disease diagnosis based on participants’ self-report is an important 
indicator for the overall awareness, recognition, health care access and utilization, and 
disease burden of this chronic condition in the general population. It is imperative to assess 
the awareness of kidney disease according to geographic areas and subpopulations deemed 
to be at a higher risk for kidney disease, because such information is helpful in 
understanding the burden or awareness of this condition. Thus, the objective of our study 
was to analyze a state-based sample from the 2011 Behavioral Risk Factor Surveillance 
System (BRFSS) in the USA to determine the awareness of kidney disease in all 50 states as 
well as the District of Columbia (D.C.). In addition, we estimated the prevalence and 
prevalence ratios of self-reported kidney disease among subpopulations stratified by 
demographic characteristics, health risk behaviors and chronic conditions.
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Materials and Methods
Behavioral Risk Factor Surveillance System
The BRFSS is a standardized telephone survey which assesses key behavioral risk factors, 
lifestyle habits and chronic illnesses and conditions among adults aged ≥ 18 years in all 50 
US states, D.C. and US territories annually. In 2011, the BRFSS collected data using a dual 
sampling frame (i.e. landline and cell phone) among adults with landline telephone or those 
with cell phone only in their households [8]. Response rates for BRFSS are calculated using 
standards set by the American Association of Public Opinion Research Response Rate 
Formula No. 4 (http://www.aapor.org/Standard_Definitions2.htm). The response rate is the 
number of respondents who completed the survey as a proportion of all eligible and likely 
eligible persons. The median survey response rate across all 50 states and D.C. was 49.7%, 
and ranged from 33.8 to 64.1%. For detailed information, see the BRFSS 2011 Summary 
Data Quality Report [9]. BRFSS data have consistently been found to provide valid and 
reliable estimates when compared with results from other national household surveys [10–
12].
Assessment of Self-Reported Kidney Disease
Diagnosis of kidney disease was ascertained by asking participants the following question: 
‘Has a doctor, nurse, or other health professional EVER told you that you have kidney 
disease (Do NOT include kidney stone, bladder infection or incontinence)?’ Responses were 
coded as ‘yes’, ‘no’, ‘don’t know/not sure’ or ‘refused’. Participants who had an affirmative 
answer to this question were considered to have self-reported kidney disease. Participants 
who answered ‘don’t know/not sure’ or ‘refused’ to this question (n = 2,838) were 
considered to have missing data and were excluded from the analyses.
Assessment of Demographic Characteristics, Health Risk Factors and Chronic Health 
Conditions
The following demographic characteristics were considered for this analysis: age at time of 
survey (years), sex, race/ethnicity [non-Hispanic (NH) white, NH black, Hispanic, NH 
other], educational attainment (<high school, high school, some college or above) and 
employment status (employed or self-employed, retired, not employed including adults who 
were unemployed, homemakers, students and those who were unable to work at the time of 
survey). Health insurance coverage at the time of survey (any vs. none), health status 
(excellent, very good, good, fair or poor), smoking status (current, former or never), heavy 
drinking (yes or no) and leisure-time physical activity (any or none) were ascertained by 
participants’ self-report. Body mass index (BMI; weight in kilo-grams/height in meters 
squared) was calculated by using self-reported weight and height. Participants were grouped 
into six categories of BMI (<18.5, 18.5–24.9, 25.0–29.9, 30.0–34.5, 35.0–39.9 and 40.0 or 
above) [13]. Six physician-diagnosed chronic health conditions that could be potentially 
associated with kidney disease according to previous studies included hypertension, 
diabetes, coronary heart disease, myocardial infarction, stroke and cancer.
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Statistical Analysis
Unadjusted and age-adjusted prevalence estimates of self-reported kidney disease were 
estimated for each state and D.C. among participants who had no missing responses on the 
kidney disease question and age (main sample). The main sample comprised adults aged 18 
years or older who participated in the 2011 BRFSS and had valid responses on the kidney 
disease question and age in all 50 US states and D.C. (n = 490,302). Of the main sample, the 
subsample further excluded pregnant women (n = 3,047) and participants with missing data 
on demographic characteristics (n = 8,299) and on selected covariates (n = 74,238). 
Participants included in the subsample (n = 404,718) had similar characteristics to the main 
sample.
The 2010 US Census age distribution of the adult population aged 18 years or older was 
used to generate the age-adjusted prevalence for each state and D.C. [14]. The age-specific 
prevalence estimate of self-reported kidney disease was estimated for men and women in the 
total sample. To further assess differences in the prevalence estimates of self-reported kidney 
disease among various subpopulations, we conducted a secondary analysis in the sub-sample 
of participants who had no missing data on all selected covariates. The demographic 
characteristics, distribution of health and behavioral risk factors, and chronic health 
conditions were compared between adults with and without self-reported kidney disease. 
The unadjusted prevalence was estimated for each subgroup, and prevalence ratios adjusted 
for age and age squared (model 1) and further adjusted for all other selected covariates 
(model 2) were estimated in log-linear regression analyses with a robust variance estimator. 
Age was centered at its grand mean in the regression models.
Two-sample t tests were used to compare equality in the distribution of covariates in adults 
with and without self-reported kidney disease. Orthogonal polynomial contrasts were used 
to test equality in the unadjusted prevalence estimates of self-reported kidney disease across 
subpopulations. All analyses were performed with SAS (version 9.2) and SUDAAN 
software (release 10.0, Research Triangle Institute, Research Triangle Park, N.C., USA). 
Sample weights, generated using an iterative proportional fitting (raking) method for 
combined landline and cell phone datasets [8], were used to account for the varying 
probabilities of complex sampling design and nonresponse. Results with a two-tailed p value 
<0.05 or a 95% CI for a prevalence ratio not including 1 were considered to be statistically 
significant.
Results
Using the main sample, both the unadjusted and age-adjusted prevalence of self-reported 
kidney disease were estimated to be 2.5%. The unadjusted prevalence varied from 1.5% in 
Iowa to 3.5% in Arizona (table 1). The age-adjusted prevalence varied from 1.4% in Iowa to 
3.5% in Arizona.
The top 5 states with the highest age-adjusted prevalence were Arizona (3.5%), Hawaii 
(3.2%), Utah (3.1%), Florida (3.1%) and Oklahoma (3.1%). The bottom 5 states with the 
lowest prevalence were North Dakota (1.9%), Maryland (1.9%), Connecticut (1.8%), 
Minnesota (1.7%) and Iowa (1.4%). There was an increasing trend in the awareness of 
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kidney disease by age for both men and women (both p < 0.0001; fig. 1). Moreover, the 
prevalence among men was lower than among women at ages 25–29 years (p < 0.01) and 
50–54 years (p < 0.05), whereas the prevalence was higher among men than among women 
at ages 60–64 years (p < 0.05) and ≥ 80 years (p < 0.05).
The characteristics of participants in the subsample according to the status of self-reported 
kidney disease are shown in table 2. In general, adults with self-reported kidney disease 
differed significantly on all selected covariates except race/ethnicity. The unadjusted 
prevalence, age-adjusted prevalence ratio and prevalence ratio adjusted for all selected 
covariates are summarized in table 3. After adjustment for possible confounding effects of 
selected covariates, the prevalence of self-reported kidney disease was about 10–20% higher 
among women, Hispanic adults, former smokers, adults with no leisure-time physical 
activity and adults who reported having diagnosed myocardial infarction than their referent 
counterparts. The awareness of kidney disease was about 30–40% higher among retirees or 
those not employed compared to the currently employed. Self-reported kidney disease 
prevalence was more than 50% higher among adults with self-reported hypertension, 
diabetes, cardiovascular disease or cancer. In contrast, adults with a high school or less than 
high school education, adults with no health insurance, heavy drinkers and adults with BMI 
<18.5 or ≥30 were less likely to report having kidney disease than their referent 
counterparts. Adults who self-rated their health as poor, fair, good or very good had an 
awareness of kidney disease about 5.7, 3.7, 2.0 and 1.3 times higher, respectively, than those 
with self-rated excellent health (p < 0.0001 for linear trend).
Discussion
Data from the BRFSS, the world’s largest telephone survey, were used to estimate an overall 
unadjusted self-reported kidney disease prevalence of 2.5%. The prevalence estimates varied 
from 1.5 to 3.5% across all 50 states and D.C. The prevalence was higher among Hispanics, 
adults who were currently unemployed, adults with diagnosed hypertension, diabetes, 
coronary heart disease, myocardial infarction, stroke or cancer, and adults who reported fair 
or poor health compared to their counterparts after adjustment for possible confounding 
effects of age and other health-related factors.
The major strength of our study was the use of a large population-based sample, which 
enabled us to provide stable prevalence estimates of self-reported kidney disease among 
adults in the general population in the USA, particularly at the state level. The large 
population-based sample also enabled us to estimate the awareness of kidney disease in 
subpopulations. Our nationwide prevalence estimate of self-reported kidney disease in 2011 
was slightly higher than that in a previous study of a national representative sample in 1999–
2000 in the USA (2.5 vs. 2.0%) [15]. Since BRFSS data provide comparable estimates to 
NHANES data in a similar time period [10–12], the higher awareness of kidney disease 
estimated in 2011 BRFSS data could be an indication of increased disease burden, higher 
awareness of this condition or both in more recent years.
The prevalence of self-reported kidney disease may be a composite indicator of awareness 
for this condition from both health care providers and patients, severity of the disease, 
Li et al. Page 5
Am J Nephrol. Author manuscript; available in PMC 2018 March 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
advances in early screening and detection, health care access and public health education. 
Inadequate knowledge and recognition and poor adherence to guidelines for clinical 
diagnosis from both primary care providers and patients may contribute to the 
underdiagnosis of CKD. Findings from a large managed care cohort suggest that only about 
14% of patients with CKD stage 3–5 have a documented diagnosis for this condition [16]. In 
a random sample of primary care physicians and nephrologists, about 59% of family 
medicine physicians and 78% of internal medicine physicians correctly identified patients 
with CKD stage 3–4 [17]. Furthermore, only 35% of US physicians have been adhering to 
guidelines of recommended clinical testing and management for CKD [18]. Meanwhile, 
inadequate patient knowledge and recognition of the risk factors, early signs and symptoms 
for CKD may delay the early detection, diagnosis and treatment of this condition [19].
Some types of CKD in their early stages may be asymptomatic and thus can be 
underdiagnosed [2]; therefore, the awareness of kidney disease may serve as an indicator of 
severe or symptomatic CKD. Findings from the NHANES data have shown that the 
prevalence of kidney disease awareness is 41.8% among persons who had clinically 
identified CKD stage 4, whereas the prevalence is 3.7, 3.5 and 7.8%, respectively, among 
persons who had CKD stage 1, 2 and 3, respectively [7]. The awareness of kidney disease is 
higher among persons with macroalbuminuria (33%) than those with microalbuminuria 
(11%) or those without proteinuria (4.5%) [7]. Moreover, as shown in the KEEP study [6], 
patients with CKD stage 1–4 who are aware of the disease are at a higher risk of progressing 
to end-stage renal disease and have a higher risk of mortality than those who are unaware of 
their disease. Our results on the graded association between self-rated health and awareness 
of kidney disease provided further support that persons with a worse health condition may 
be more likely to seek medical assessment and thus more likely to be diagnosed with the 
disease.
Consistent with previous findings [6, 7, 19], our results demonstrated that persons with 
diagnosed hypertension and diabetes have a high awareness of kidney disease after 
adjustment for age and other health risk factors and chronic conditions. Hypertension and 
CKD are linked with each other in a pathogenic bidirectional fashion such that high blood 
pressure leads to the worsening of kidney function, whereas kidney disease causes resistant 
hypertension [20]. A recent study using data from NHANES 1999–2006 showed that the 
prevalence of CKD stage 1–4 combined is 32.0% among persons with diagnosed 
hypertension, whereas the awareness of kidney disease is 9.1%, suggesting substantially low 
awareness of CKD [21]. Diabetic nephropathy is a major microvascular complication due to 
long-term harmful effects of hyperglycemia among persons with diabetes [22]. Among 
participants aged 20 years or older, the prevalence of CKD stage 1–4 combined was 39.6% 
among persons with diagnosed diabetes [23], whereas the awareness of kidney disease based 
on the NHANES 1999–2004 data was 17.8%, also suggesting substantially low awareness of 
CKD [7].
There were several limitations in this study. Firstly, the question for measuring kidney 
disease did not specify the type and duration of kidney disease and thus we could not rule 
out the possibility of acute kidney disease episodes and other types of kidney disorders. 
Persons who had never undergone kidney disease-related clinical assessment or diagnosis 
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(e.g. in early CKD stages or had no kidney disease-related clinical symptoms or had no 
health care access) may not have been told by health professionals that they had kidney 
disease. It was also possible that persons who had a clinical diagnosis of kidney disease had 
not been told by health professionals or had forgotten the diagnosis at the time of survey. 
Thus, information bias could have led to underestimation of the prevalence. Secondly, due to 
lack of information on medication for hypertension, diabetes, cardiovascular disease or 
cancer, we were unable to assess whether an elevated prevalence of CKD was associated 
with certain types of medications. Findings from a previous study have shown that among 
persons with hypertension, those who are on medication have a higher prevalence of CKD 
stage 3 and 4 than those without medication [21]. Therefore, future research on the 
association between specific types of medication for hypertension, diabetes or 
cardiovascular disease and risk of CKD may be warranted. Thirdly, detection bias may be 
possible as our results showed that persons without health insurance were less likely than 
those with health insurance to report a kidney disease diagnosis. Fourthly, the BRFSS survey 
excludes adults who have been institutionalized or are hospitalized; therefore, this exclusion 
may have led us to underestimate the kidney disease awareness among US adults.
In sum, using data from a large population-based survey, we found that the prevalence of 
self-reported kidney disease was about 2.5% among US adults. Persons who had 
hypertension, diabetes, cardiovascular disease or cancer had about 50–90% higher 
prevalence compared with those without such chronic conditions. As CKD has emerged as 
an important public health issue, greater efforts are warranted to improve the awareness, 
early detection, clinical management and surveillance for CKD.
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Fig. 1. 
Crude prevalence estimates of self-reported kidney disease by age and sex, BRFSS 2011. *p 
< 0.05, **p < 0.01.
Li et al. Page 9
Am J Nephrol. Author manuscript; available in PMC 2018 March 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Li et al. Page 10
Table 1
Prevalence of self-reported kidney diseases among adults aged 18 years or older in the USA, 2011 BRFSS
State n Unadjusted prevalence, % Age-adjusted prevalence, %
All 490,302 2.5 (0.1) 2.5 (0.1)
Alabama 7,608 2.7 (0.2) 2.6 (0.2)
Alaska 3,494 2.3 (0.3) 2.7 (0.4)
Arizona 6,379 3.5 (0.4) 3.5 (0.4)
Arkansas 4,666 2.9 (0.3) 2.9 (0.3)
California 16,898 2.6 (0.2) 2.7 (0.2)
Colorado 13,384 2.2 (0.2) 2.3 (0.2)
Connecticut 6,704 1.9 (0.2) 1.8 (0.2)
Delaware 4,712 2.5 (0.3) 2.4 (0.3)
District of Columbia 4,463 2.7 (0.3) 2.9 (0.3)
Florida 12,192 3.3 (0.2) 3.1 (0.2)
Georgia 9,826 2.8 (0.2) 3.0 (0.2)
Hawaii 7,523 3.3 (0.3) 3.2 (0.3)
Idaho 5,985 2.4 (0.2) 2.5 (0.2)
Illinois 5,447 2.8 (0.4) 2.8 (0.4)
Indiana 8,384 2.1 (0.2) 2.1 (0.2)
Iowa 7,249 1.5 (0.2) 1.4 (0.2)
Kansas 20,536 2.3 (0.1) 2.3 (0.1)
Kentucky 10,716 2.5 (0.2) 2.4 (0.2)
Louisiana 10,813 2.6 (0.2) 2.6 (0.2)
Maine 13,101 2.4 (0.2) 2.2 (0.1)
Maryland 9,939 1.9 (0.2) 1.9 (0.2)
Massachusetts 21,835 1.9 (0.1) 1.9 (0.1)
Michigan 10,904 3.0 (0.2) 3.0 (0.2)
Minnesota 15,199 1.7 (0.1) 1.7 (0.1)
Mississippi 8,808 2.4 (0.2) 2.4 (0.2)
Missouri 6,337 2.3 (0.2) 2.3 (0.2)
Montana 10,163 2.6 (0.2) 2.4 (0.2)
Nebraska 25,221 2.2 (0.1) 2.2 (0.1)
Nevada 5,380 2.5 (0.3) 2.6 (0.3)
New Hampshire 6,250 2.5 (0.3) 2.4 (0.3)
New Jersey 15,090 2.0 (0.2) 1.9 (0.2)
New Mexico 9,316 3.1 (0.2) 3.0 (0.2)
New York 7,576 2.8 (0.3) 2.8 (0.3)
North Carolina 11,363 2.2 (0.2) 2.2 (0.2)
North Dakota 5,234 1.9 (0.2) 1.9 (0.2)
Ohio 9,771 2.5 (0.2) 2.4 (0.2)
Oklahoma 8,482 3.1 (0.2) 3.1 (0.2)
Oregon 6,172 2.5 (0.2) 2.4 (0.2)
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State n Unadjusted prevalence, % Age-adjusted prevalence, %
Pennsylvania 11,352 2.5 (0.2) 2.4 (0.2)
Rhode Island 6,410 2.3 (0.2) 2.2 (0.2)
South Carolina 12,778 2.2 (0.2) 2.1 (0.2)
South Dakota 8,189 2.0 (0.2) 1.9 (0.2)
Tennessee 5,841 2.1 (0.3) 2.1 (0.3)
Texas 14,767 2.7 (0.2) 2.8 (0.2)
Utah 12,507 2.8 (0.2) 3.1 (0.2)
Vermont 7,006 2.2 (0.2) 2.1 (0.2)
Virginia 6,507 1.9 (0.3) 2.0 (0.3)
Washington 14,553 2.3 (0.2) 2.3 (0.2)
West Virginia 5,235 2.8 (0.2) 2.6 (0.2)
Wisconsin 5,242 2.2 (0.3) 2.1 (0.3)
Wyoming 6,795 2.1 (0.2) 2.1 (0.2)
Minimum 3,494 1.5 1.4
Maximum 25,221 3.5 3.5
Median 8,384 2.4 2.4
Total numbers included participants who had complete data on age and self-reported kidney disease in all 50 states as well as D.C. Age-adjusted 
prevalences were standardized using the 2010 US Census population age distribution (i.e. age adjustment weights of 0.130762, 0.350158, 0.347408 
and 0.171672 for age groups 18 – 24, 25 – 44, 45 – 64 and ≥65 years, respectively) [14]. Values in parentheses represent standard errors.
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Table 3
Prevalence and prevalence ratios of self-reported kidney disease according to demographic characteristics, 
health risk factors and chronic condition profiles among men and nonpregnant women aged 18 years or older 
in the USA, BRFSS 2011
Characteristic Unadjusted prevalence Prevalence ratio
model 1 model 2
Sex Men (Ref) 2.3 (0.1) 1.0 (Ref) 1.0 (Ref)
Women 2.6 (0.1)*** 1.1 (1.0 – 1.1) 1.1 (1.0 – 1.2)
Race/ethnicity Non-Hispanic white (Ref) 2.5 (0.1) 1.0 (Ref) 1.0 (Ref)
Non-Hispanic black 2.6 (0.2) 1.3 (1.1 – 1.5) 1.0 (0.9 – 1.1)
Hispanic 2.5 (0.2) 1.4 (1.2 – 1.7) 1.2 (1.0 – 1.4)
Other race/ethnicity 2.4 (0.2) 1.3 (1.0 – 1.5) 1.1 (0.9 – 1.3)
Education Some college or above (Ref) 2.2 (0.1) 1.0 (Ref) 1.0 (Ref)
High school 2.4 (0.1) 1.0 (1.0 – 1.1) 0.8 (0.8 – 0.9)
Less than high school 3.8 (0.2)*** 1.6 (1.4 – 1.8) 0.9 (0.8 – 1.0)
Employment Employed (Ref) 1.4 (0.1) 1.0 (Ref) 1.0 (Ref)
Retired 5.0 (0.1)*** 1.7 (1.5 – 1.9) 1.3 (1.1 – 1.4)
Not employed1 3.3 (0.1)*** 2.4 (2.2 – 2.7) 1.4 (1.2 – 1.5)
Health insurance Any (Ref) 2.7 (0.1) 1.0 (Ref) 1.0 (Ref)
None 1.5 (0.1)*** 0.9 (0.7 – 1.0) 0.7 (0.6 – 0.8)
Smoking status Never smoked (Ref) 2.0 (0.1) 1.0 (Ref) 1.0 (Ref)
Former smoker 3.4 (0.1)*** 1.2 (1.1 – 1.3) 1.1 (1.0 – 1.2)
Current smoker 2.5 (0.1)** 1.4 (1.2 – 1.6) 1.0 (0.9 – 1.2)
Heavy drinking No (Ref) 2.6 (0.1) 1.0 (Ref) 1.0 (Ref)
Yes 1.4 (0.1)*** 0.7 (0.5 – 0.8) 0.8 (0.6 – 0.9)
Leisure-time physical activity Active (Ref) 2.0 (0.1) 1.0 (Ref) 1.0 (Ref)
Inactive 3.8 (0.1)*** 1.6 (1.5 – 1.7) 1.1 (1.0 – 1.2)
BMI, kg/m2 <18.5 2.3 (0.3) 1.2 (0.9 – 1.6) 0.9 (0.7 – 1.2)
18.5 – 24.9 (Ref) 1.9 (0.1) 1.0 (Ref) 1.0 (Ref)
25.0 – 29.9 2.5 (0.1)*** 1.1 (1.0 – 1.3) 1.0 (0.9 – 1.1)
30.0 – 34.5 2.8 (0.1)*** 1.3 (1.2 – 1.4) 0.8 (0.7 – 0.9)
35.0 – 39.9 3.3 (0.2)*** 1.6 (1.4 – 1.8) 0.8 (0.7 – 0.9)
≥40 4.7 (0.3)*** 2.4 (2.1 – 2.8) 0.9 (0.8 – 1.1)
High BP No (Ref) 1.3 (0.1) 1.0 (Ref) 1.0 (Ref)
Yes 5.1 (0.1)*** 2.9 (2.7 – 3.2) 1.9 (1.7 – 2.1)
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Characteristic Unadjusted prevalence Prevalence ratio
model 1 model 2
Diabetes No (Ref) 1.9 (0.1) 1.0 (Ref) 1.0 (Ref)
Yes 8.2 (0.3)*** 3.1 (2.8 – 3.3) 1.7 (1.5 – 1.8)
CVD No (Ref) 1.9 (0.1) 1.0 (Ref) 1.0 (Ref)
Yes 8.8 (0.3)*** 2.9 (2.7 – 3.2) 1.5 (1.4 – 1.6)
Cancer No (Ref) 2.1 (0.1) 1.0 (Ref) 1.0 (Ref)
Yes 5.8 (0.2)*** 1.7 (1.6 – 1.9) 1.5 (1.3 – 1.6)
Self-reported health status Excellent (Ref) 0.8 (0.1) 1.0 (Ref) 1.0 (Ref)
Very good 1.2 (0.1)*** 1.5 (1.2 – 1.9) 1.3 (1.1 – 1.7)
Good 2.2 (0.1)*** 2.5 (2.0 – 3.1) 2.0 (1.6 – 2.5)
Fair 5.7 (0.2)*** 5.7 (4.7 – 7.1) 3.7 (3.0 – 4.6)
Poor 12.2 (0.5)*** 11.2 (9.1 – 13.8) 5.7 (4.5 – 7.2)
Values in parentheses represent standard errors or 95% CIs, as appropriate. Prevalence ratios were obtained using log-linear regression models with 
a robust variance estimator. In model 1, prevalence ratios were adjusted for age (centered at grand mean) and age squared. In model 2, prevalence 
ratios were adjusted for age, age squared and all other covariates listed in the table.
**p < 0.01,
***p < 0.001 (two-sample t tests were used to test for equality in the prevalence of self-reported kidney disease between the designated group and 
the referent group). BP = Blood pressure; CVD = cardiovascular disease, including coronary heart disease, myocardial infarction or stroke; Ref = 
referent group.
1
Including adults who were unemployed, homemakers, students or unable to work.
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